... price controls 22, 23, 149; utilization controls 79; value-based pricing 137–138, 325; see also National Health ... Vyndaqel 518 Vytorin 161,205 WAC see Wholesale Acquisition Cost (WAC) Wales 8,235 WHO see World Health Organization ...
... tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel. Vyndaqel currently sells for about $100,000 a year outside the United States as a ...
... price, and therefore the uptake of this therapy may be limited.37 Although the ESC guidelines recommend its use, European countries have adopted different ... tafamidis beneficial? Role of tafamidis in patients with advanced disease.
... price by using regression analysis. Then, the study will determine which index has a closer relationship with ... Vyndaqel/Vyndamax/Vynmac, Xtandi, Inlyta, Enbrel, Sutent, and Sulperazon. Pfizer operates internationally, and its ...
... price $450,000 annual list price $345,000 aver- age effective net annual price 80 mg once a day Tafamidis meglu- mine Stabilizer Neuropathy/ Oral cardiomyopathy 20 mg once a day Tafamidis free salt Stabilizer Diflunisal Stabilizer ...
... tafamidis in the case of transthyretin amyloidosis (Maurer et al., 2018). The costs of tafamidis therapy regimen are ... price tag of these therapies. With the availability of new treatments and the better outcome in the case of ...
An array of examples is given to illustrate various technical issues. The text has been written for biologists and statisticians using models for making inferences from empirical data.
This book provides a practical guide to the field of neuromuscular pathology including muscle, peripheral nerve, and skin biopsies with biopsy interpretation.
... tafamidis) (Obici et al., 2012) have been tested in ATTR amyloidosis leading to licensing of a novel agent ... Price-Troska, T. L., et al. (2003). Immunoglobulin light chain variable (V) region genes influence clinical presentation ...
... Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379(11): 1007-16 ... price Hibernation or Transformation? Frontiers in Cardiovascular Drug Discovery, Vol. 6 135.